Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects

Clinical and Vaccine Immunology

Volumn 15, Issue 5, 2008, Pages 773-782

  Koelle, David M ^a,b,c   Magaret, Amalia ^a,c   McClurkan, Christopher L ^a   Remington, Michael L ^a   Warren, Terri ^d   Teofilovici, Florentina ^e   Wald, Anna ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Westover Heights Clinic   (United States)

^e Antigenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AG 702; CREATINE KINASE; EPITOPE; GLYCOPROTEIN B; HEAT SHOCK PROTEIN 70; HERPES SIMPLEX VACCINE; HLA A ANTIGEN; PEPTIDE VACCINE; TETRAMER; VALACICLOVIR; VIRUS PROTEIN; GLYCOPROTEIN D HERPES SIMPLEX VIRUS TYPE 2; GLYCOPROTEIN D-HERPES SIMPLEX VIRUS TYPE 2; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; SUBUNIT VACCINE; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ALLERGY; ARTICLE; BACKACHE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE TENDERNESS; INJECTION SITE WARMTH; IRON DEFICIENCY ANEMIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; TENSION HEADACHE; UPPER RESPIRATORY TRACT INFECTION; VIRION; VIRUS REPLICATION; ADOLESCENT; CHEMISTRY; GENETICS; GENITAL HERPES; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SAFETY;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HLA-A ANTIGENS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MIDDLE AGED; SAFETY; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 46249092917     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00020-08     Document Type: Article

References (53)

1. Arrode, G., J. S. Finke, H. Zebroski, F. P. Siegal, and R. M. Steinman. 2005. CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur. J. Immunol. 35:159-170.
2. Ashley, R. A., J. Militoni, F. Lee, A. Nahmias, and L. Corey. 1988. Comparison of Western blot (immunoblot)and glycoprotein G-specific immunoblot for detecting antibodies to herpes simplex types 1 and 2 in human sera. J. Clin. Microbiol. 26:662-667.
3. Binder, R. J., and P. K. Srivastava. 2005. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6:593-599.
4. Blaney, J. E., E. Nobusawa, M. A. Brehm, R. H. Bonneau, L. M. Mylin, T. M. Fu, Y. Kawoaka, and S. S. Tevethia. 1998. Immunization with a single major histocompatibility class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72:9567-9574.
5. Corey, L., A. Wald, C. L. Celum, and T. C. Quinn. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35:435-445.
6. Corey, L., A. Wald, R. Patel, S. L. Sacks, S. K. Tyring, T. Warren, J. M. Douglas, Jr., J. Paavonen, R. A. Morrow, K. R. Beutner, L. S. Stratchounsky, G. Mertz, O. N. Keene, H. A. Watson, D. Tait, and M. Vargas-Cortes. 2004. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350:11-20.
7. Cunningham, A. L., and T. C. Merigan. 1983. Gamma interferon production appears to predict time of recurrence of herpes labialis. J. Immunol. 130:2397-2400.
8. Dekker, C. L., S. F. Adair, R. Sekulovich, N. Niland, and R. L. Burke. 1992. A phase I study of recombinantly produced herpes simplex virus (HSV) glycoproteins gD2 and gB2 combined with a novel adjuvant MF59/MTP-PE. Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1431, p. 349.
9. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:774-779.
10. Dolan, A., F. E. Jamieson, C. Cunningham, B. C. Barnett, and D. J. McGeoch. 1998. The genome sequence of herpes simplex virus type 2. J. Virol. 72:2010-2021.
11. Engler, O. B., W. J. Dai, A. Sette, I. P. Hunziker, J. Reichen, W. J. Pichler, and A. Cerny. 2001. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol. Immunol. 38:457-465.
12. Frenkel, L., E. Pineda, H. Hall, M. Dillon, and Y. Bryson. 1989. A prospective study of the effects of acyclovir treatment on the HSV-2 lymphoproliferative response of persons with frequently recurring HSV-2 genital infections. J. Infect. Dis. 159:845-850.
13. Fu, C. L., Y. L. Ye, Y. L. Lee, and B. L. Chiang. 2003. Both allergen-specific CD4 and CD8 type 2 T cells decreased in asthmatic children with immunotherapy. Pediatr. Allergy Immunol. 14:284-291.
14. Gahery, H., N. Daniel, B. Charmeteau, L. Ourth, A. Jackson, M. Andrieu, J. Choppin, D. Salmon, G. Pialoux, and J. G. Guillet. 2006. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22:684-694.
15. Gray, C. M., J. Lawrence, E. A. Ranheim, M. Vierra, M. Zupancic, M. Winters, J. Altman, J. Montoya, A. Zolopa, J. Schapiro, A. T. Haase, and T. C. Merigan. 2000. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. AIDS Res. Hum. Retroviruses 16:1357-1369.
16. + T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 80:5509-5515.
17. Johnson, C., T. P. Monath, N. Kanesa-Thasan, D. Mathis, C. Miller, S. Shapiro, R. Nichols, K. McCarthy, A. Deary, and P. Bedford. 2005. Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum. Vaccin. 1:24-29.
18. Jonsson, M. K., and B. Wahren. 2004. Sexually transmitted herpes simplex viruses. Scand. J. Infect. Dis. 36:93-101.
19. Karahocagil, M. K., T. Buzgan, H. Irmak, H. Karsen, H. Akdeniz, and N. Akman. 2006. Comparison of intramuscular and intradermal applications of hepatitis B vaccine in hemodialysis patients. Ren. Fail. 28:561-565.
20. Khanna, K. M., A. J. Lepisto, and R. L. Hendricks. 2004. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol. 25:230-234.
21. Kit, S., M. Kit, H. Qavi, D. Trkula, and H. Otsuka. 1983. Nucleotide sequence of the herpes simplex virus type 2 (HSV-2) thymidine kinase gene and predicted amino acid sequence of thymidine kinase polypeptide and its comparison with the HSV-1 thymidine kinase gene. Biochim. Biophys. Acta 741:158-170.
22. Koelle, D. M., H. Chen, M. A. Gavin, A. Wald, W. W. Kwok, and L. Corey. 2001. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 166:4049-4058.
23. Koelle, D. M., and L. Corey. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
24. + T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 68:2803-2810.
25. Koelle, D. M., Z. Liu, C. M. McClurkan, M. Topp, S. R. Riddell, E. G. Pamer, A. S. Johnson, A. Wald, and L. Corey. 2002. Expression of cutaneous lymphocyte-associated antigen by CD8+ T-cells specific for a skin-tropic virus. J. Clin. Investig. 110:537-548.
26. Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank, and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Investig. 101:1500-1508.
27. Kumaraguru, U., M. Gierynska, S. Norman, B. D. Bruce, and B. T. Rouse. 2002. Immunization with chaperone-peptide complex includes low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J. Virol. 76:136-141.
28. Lalvani, A., T. Dong, G. Ogg, A. A. Patham, H. Newell, A. V. Hill, A. J. McMichael, and S. Rowland-Jones. 1997. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. J. Immunol. Methods 15:65-77.
29. Lekstrom-Himes, J. A., P. Hohman, T. Warren, A. Wald, J.-M. Nam, L. Corey, and S. E. Straus. 1999. Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. J. Infect. Dis. 179:1077-1085.
30. Maeda, H., H. Sahara, Y. Mori, T. Torigo, K. Kamiguchi, Y. Tamura, K. Hirata, and N. Sato. 2007. Biological heterogeneity of the peptide-binding motif of the 70-kDa heat shock protein by surface plasmon resonance analysis. J. Biol. Chem. 282:26956-26962.
31. Marsh, S. G. E., P. Parham, and L. D. Barber. 2000. The HLA factsbook. Academic Press, San Diego, CA.
32. Mikszta, J. A., V. J. Sullivan, C. Dean, A. M. Waterston, J. B. Alarcon, J. P. Dekker III, J. M. Brittingham, J. Huang, C. R. Hwang, M. Ferriter, G. Jiang, K. Mar, K. U. Saikh, B. G. Stiles, C. J. Roy, R. G. Ulrich, and N. G. Harvey. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:278-288.
33. Novy, P., M. Quigley, X. Huang, and Y. Yang. 2007. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J. Immunol. 179:8243-8251.
34. O'Flynn, K., A. M. Krensky, P. C. Beverley, S. J. Burakoff, and D. C. Linch. 1985. Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. Nature 313:686-687.
35. Pack, C. D., U. Kumaraguru, S. Suvas, and B. T. Rouse. 2005. Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with herpes simplex virus. Vaccine 23:3526-3534.
36. Pockley, A. G. 2003. Heat shock proteins as regulators of the immune response. Lancet 362:469-476.
37. Posavad, C. M., D. M. Koelle, M. F. Shaughnessy, and L. Corey. 1997. Severe genital herpes infections in HIV-infected individuals with impaired HSV-specific CD8+ cytotoxic T lymphocyte responses. Proc. Natl. Acad. Sci. USA 94:10289-10294.
38. Sloan, D. D., J. Y. Han, T. K. Sandifer, M. Stewart, A. J. Hinz, M. Yoon, D. C. Johnson, P. G. Spear, and K. R. Jerome. 2006. Inhibition of TCR signaling by herpes simplex virus. J. Immunol. 176:1825-1833.
39. Smith, C. M., N. S. Wilson, J. Waithman, J. A. Villadangos, F. R. Carbone, W. R. Heath, and G. T. Belz. 2004. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat. Immunol. 5:1143-1148.
40. Smith, J. G., X. Liu, R. M. Kaufhold, J. Clair, and M. J. Caulfield. 2001. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 8:871-879.
41. Srivastava, P. K. 2000. Immunotherapy of human cancer: lessons from mice. Nat. Immunol. 1:363-366.
42. Stanberry, L. R., S. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denes, P. Vandepapeliere, and G. Dubin. 2002. Prophylactic vaccination against genital herpes with adjuvanted recombinant glycoprotein D vaccine: two randomized controlled trials. N. Engl. J. Med. 347:1652-1661.
43. Straus, S. E., L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, S. F. Adair, and C. L. Dekker. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463.
44. Straus, S. E., A. Wald, R. G. Kost, R. McKenzie, A. G. M. Langenberg, P. Hohman, J. Lekstrom, E. Cox, M. Nakamura, R. Sekulovich, A. Izu, C. Dekker, and L. Corey. 1997. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virua type 2 glycoproteins B and D: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176:1129-1134.
45. + herpes simplex virus-specific cytotoxic T lymphocyte clones recognize diverse virion protein antigens. J. Virol. 66:1622-1634.
46. Tigges, M. A., S. Leng, D. C. Johnson, and R. L. Burke. 1996. Human herpes simplex (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J. Immunol. 156:3901-3910.
47. Trotti, A., R. Byhardt, J. Stetz, C. Gwede, B. Corn, K. Fu, L. Gunderson, B. McCormick, M. Morrisintegral, T. Rich, W. Shipley, and W. Curran. 2000. Common toxicity criteria: version 2.0, an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 47:13-47.
48. Verjans, G. M. G. M., R. Q. Hintzen, J. M. van Dun, A. Poot, J. C. Milikan, J. D. Laman, A. W. Langerak, P. R. Kinchington, and A. D. M. E. Osterhaus. 2007. Selective retention of herpes simplex virus specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. USA 104:3496-3501.
49. Wald, A., L. Corey, R. Cone, A. Hobson, G. Davis, and J. Zeh. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J. Clin. Investig. 99:1092-1097.
50. Wald, A., A. G. Langenberg, E. Krantz, J. M. Douglas, Jr., H. H. Handsfield, R. P. DiCarlo, A. A. Adimora, A. E. Izu, R. A. Morrow, and L. Corey. 2005. The relationship between condom use and herpes simplex virus acquisition. Ann. Intern. Med. 143:707-713.
51. Wald, A., J. Zeh, G. Barnum, L. G. Davis, and L. Corey. 1996. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 124:8-15.
52. Yang, S., K. Y. Tsang, and J. Schlom. 2005. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin. Cancer Res. 11:5603-5615.
53. Zhu, J., D. M. Koelle, J. Cao, J. Vezquez, M. L. Huang, F. Hladik, A. Wald, and L. Corey. 2007. Peripheral virus-specific CD8+ T cells contiguous to sensory nerve endings limit HSV-2 reactivation in human genital skin. J. Exp. Med. 204:595-603.